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strain may contribute to delayed AGE removal from and earlyDifferential expression of renal AGE-receptor genes in NOD
AGE deposition in kidney tissues. This may act as a triggermice: Possible role in nonobese diabetic renal disease.
for those AGE-R genes involved in growth-promoting changes,Background. Nonobese diabetic mice (NOD) are prone to
leading to DN in this strain.glomerular pathology, which is accelerated with the onset of
diabetes. Advanced glycation end product (AGE) interactions
with AGE-receptors (AGE-Rs) in kidneys can contribute to
glomerular injury and diabetic nephropathy (DN). The signifi- A substantial subset of diabetic patients develops se-cant elevation in kidney AGE deposits noted in prediabetic
vere complications, regardless of glycemic control andNOD mice suggested that delayed AGE turnover in this model
disease duration [1, 2], emphasizing that genetic suscepti-may contribute to its propensity toward DN.
Methods. To explore whether excess tissue AGE was linked bility is an important factor in the host response to the
to altered AGE-R status in the kidney, mRNA/protein expres- diabetic environment. Several genes have been impli-
sion, and of several AGE-Rs [AGE-R1, AGE-R2, AGE-R3, cated in the development of diabetic complications, in-scavenger receptor II (ScR-II), and receptor for AGE (RAGE)],
cluding those related to hypertension [1], angiotensin-was determined in renal cortex and in mesangial cells (MCs)
converting enzyme (ACE), or angiotensin II receptorsisolated from ND-, D-NOD, and ILE mice (N 5 20 per group).
Ligand binding, receptor site number, and affinity were deter- [1, 2]. Although no major gene loci have been established
mined in MCs from the same mouse groups. as yet, it is presumed that such genes are principally
Results. Prediabetic NOD kidney AGE-R1 mRNA and pro- linked to kidney disease and are inducible by diabetes.tein level were threefold lower than that of ILE mice (P ,
Mounting evidence indicates that glucose-derived gly-0.01), while AGE-R3 mRNA was enhanced by twofold (P ,
coxidation derivatives or advanced glycation end prod-0.05) and AGE-R2, RAGE, and ScR-II mRNA remained close
to normal (ILE). The onset of diabetes in NOD mice, while ucts (AGEs) and AGE receptors (AGE-R) play a major
enhancing AGE-R1 mRNA expression by approximately two- role in normal tissue homeostasis, aging, and the devel-
fold, failed to raise it above the normal (ILE) level, despite opment of diabetic complications [3–8]. In the kidney,
increases in tissue, and serum AGE. The latter was associated
AGE-Rs of mesangial cells (MCs) mediate ingestion andwith higher elevation in AGE-R3 (sixfold, P , 0.05), RAGE
degradation of AGEs [9] and regulate cytokine, growth(twofold, P 5 NS), and ScR-II mRNA (2.8-fold, P 5 NS)
factor, and extracellular matrix (ECM) synthesis [6, 10,above control. MCs from prediabetic NOD mice showed a
threefold lower level of AGE-R1 mRNA (P , 0.02 vs. ILE) 11], all major contributors to renal disease [12]. Presum-
and AGE-R1-protein, and AGE-binding activity (,40% of ably, impaired function of this system can occur at multi-
control ILE). In contrast, AGE-R3 mRNA was enhanced (two- ple points, causing delayed cellular AGE processingfold), while AGE-R2 showed no change. Cultured ND-NOD
and/or enhanced AGE toxicity; however, no receptor-MCs displayed only one fourth of the AGE-binding sites/cell
based defects have been reported. We have identifiedpresent on ILE MCs (1.6 3 106 vs. 6.6 3 106, P , 0.05), which
after the onset of diabetes rose to the normal range (7.0 3 106/ three MC-associated molecules that interact with AGEs:
cell), but failed to exceed it. (1) AGE-R1, a 48 kD AGE-binding and endocytosis-
Conclusions. Reduced AGE-R1 gene expression in this mediating protein [13, 14], initially copurified with the
oligosaccharyl-transferase (OST) complex; (2) AGE-R2,
an 80 to 87 kD AGE-inducible tyrosine-phosphorylatedKey words: glycoxidation, kidney disease, receptors, diabetic complica-
tions, advanced glycation end product. protein kinase C substrate, copurified with AGE-R1 [13,
15–17]; (3) and AGE-R3 [18], a high-affinity AGE-bind-Received for publication October 29, 1999
ing peptide [18], also known as galectin-3, linked to cellu-and in revised form April 6, 2000
Accepted for publication May 19, 2000 lar activation, anti-apoptotic events, and cellular anti-
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cDNA sequences and chromosomal location of all three blood was collected, and mice were perfused extensively
molecules are identified and found to be present on renal through the aorta with sterile phosphate-buffered saline
MCs and other cells (unpublished data) [13, 17, 19]. (PBS) containing RNAse inhibitor (Boehringer Mann-
Other known AGE-binding molecules with diverse spec- heim, Indianapolis, IN, USA). For total RNA membrane
ificities not limited to AGEs and with no clear role in and total protein extraction, kidney cortices were snap
MC function include scavenger receptor II (ScR-II) and frozen in liquid nitrogen immediately after removal or
receptor for AGE (RAGE) [21–24]. Reactive AGE pre- were gradually frozen in OCT compound (Miles Inc.,
cursors include substances that have cell-activating, pro- Elkhart, IN, USA) for immunostaining [30, 31].
oxidant and/or cross-linking properties, while their final
elimination in animals and humans depends on normal Mesangial cell culture
renal function [25–27]. Thus, impaired AGE clearance, Glomerular MCs from each animal group were iso-
as in renal failure, can lead to significant retention of lated and characterized, as described [9–11]. Two differ-
AGEs in blood and tissues and can promote tissue injury, ent cell preparations from each mouse group were cul-
notably within the glomerulus [10, 11]. tured in complete medium [2/3 Dulbecco’s modified
Among the various animal models of spontaneous
Eagle’s medium (DMEM):1/3 F12, supplemented with
IDDM, over 85% of the female nonobese diabetic
1 mmol/L glutamine, penicillin at 100 U/mL, streptomy-(D-NOD) mice develop an autoimmune type I diabetes
cin at 100 mg/mL, and 10% fetal bovine serum; GIBCO,(IDDM), appearing within the first three months of life
Gaithersburg, MD, USA]. Cells were passaged weeklyand associated with evidence of early kidney lesions
(for 8 to 10 passages).[28, 29]. In addition, nondiabetic NOD (ND-NOD) mice
exhibit a propensity to develop mesangial ECM deposits
Antibodies, ligands, and assays
and increased cellularity, which progresses to glomerulo-
Rabbit polyclonal antisera and the respective affinity-sclerosis after the onset of diabetes [29]. We have re-
purified IgG raised against recombinant human AGE-ported that NOD mice exhibit disproportionally high
R1 (rhAGE-R1) and AGE-R2 (rhAGE-R2) have pre-kidney tissue AGE levels, transforming growth factor-b1
viously exhibited excellent immunoreactivity against hu-(TGF-b1), and insulin-like growth factor-1 (IGF-1), to-
man or murine tissues and cells [13, 17, 32]. In the presentgether with evident glomerular hypertrophy at a young
mouse studies, anti–AGE-R2, although adequate forage, compared with other strains, for example, Swiss
Western analysis, exhibited weak cross-reactivity againstJackson Laboratory (SJL) mice [30]. The accumulation
of AGEs even in ND-NOD kidneys turned our attention mouse kidney tissue. Rat monoclonal antibody (mAb)
to impaired tissue turnover of these substances, possibly specific to murine AGE-R3 was purified from culture
AGE-R related. This could trigger renal cell dysfunction supernatants of hybridoma M3/38 (ATCC TIB166), us-
prior to the onset but be exacerbated by diabetes in this ing a protein G-sepharose column (Boehringer Mann-
strain. heim Biochemicals) and used together with an isotypic
In this report, we focus on the expression and AGE- rat IgG (Sigma Chemical Co., St. Louis, MO, USA)
binding activity of several molecules known to interact [18, 32]; anti–ScR-II and anti-RAGE reagents were not
with AGEs in renal cortical tissue, as well as in isolated available for these studies.
NOD MCs prior to and after the development of IDDM. Low-endotoxin bovine serum albumin (BSA; Sigma
The findings revealed a selective decrease in AGE-R1 Chemical Co.) passed over an affi-Gel Blue column (Bio-
gene expression in the kidney associated with reduced Rad, Hercules, CA, USA), a heparin-Sepharose CL6B
AGE-R binding capacity despite the significant rise in column (Pharmacia, Uppsala, Sweden), and an endotoxin-
other AGE-R components. These changes, when com-
binding affinity column (Pierce, Rockford, IL, USA) to re-
bined, may account in part for abnormal AGE processing
move various contaminants were incubated with or with-and in part for growth effects that contribute to the
out 0.5 mol/L d-glucose in 0.2 mol/L phosphate bufferglomerulopathy specific to NOD mice.
(pH 7.4) at 378C for eight weeks under sterile conditions.
Low molecular weight reactants and free glucose were
METHODS removed by dialysis against PBS. AGE levels, based on
an AGE enzyme-linked immunosorbent assay (ELISA)Animals
[33] were AGE-BSA, 250 U/mg protein, and unmodifiedDiabetic-NOD, ND-NOD (3 to 6 months old), and
BSA, 0.9 U/mg protein. Aliquots of each preparationage-matched ILE (diabetes resistant, genetically related
were iodinated using the Iodo-Beads (Pierce) and afterto NOD) mice (N 5 20 per group) were obtained from
trichloroacetic acid (TCA; 20%) precipitation, approxi-Dr. Hattori (Joslin Diabetic Center, Boston, MA, USA).
mately 95% of 125I was protein bound (specific activityAge-matched SJL mice were from Jackson Laboratory
(Bar Harbor, ME, USA). After sacrifice by decapitation, of approximately 0.8 to 1.0 3 103/ng of protein) [32].
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Serum and kidney tissue AGE determination ng/mL pepstatin, 2 mmol/L phenylmethylsulfonyl fluo-
ride (PMSF), and 10 mg/mL aprotinin [11, 31]. SectionsKidney tissues were homogenized and digested as de-
of kidney cortices were homogenized with a Douncescribed [9, 26]. The supernatant of kidney homogenates
homogenizer in the presence of protease inhibitors, asand serum samples was used for AGE determination by
described previously in this article, and washed with ice-an AGE-ELISA [33]. Urine creatinine (Stanbio Labora-
cold PBS to eliminate blood contamination and nondis-tory, San Antonio, TX, USA) and albumin levels were
solved fragments. Nuclei and cell debris were removedmeasured accordingly (by an anti-mouse antibody-based
after centrifugation at 1100 r.p.m. for 10 minutes. TheELISA) [29, 30].
crude membrane fraction was separated from the cyto-
solic fraction by centrifugation at 15,000 r.p.m. for 20AGE receptor immunolocalization
minutes at 48C, and the resuspendent pellet was centri-Coronal 4 mm thick sections were cut from frozen
fuged at 27,000 r.p.m. for one hour at 48C. The pelletedkidney samples and fixed in Carnoy’s fixative. The sec-
partially purified membrane extract was resuspended intions, after preincubation with goat serum for 10 minutes,
PBS, and the protein content was determined using thewere coated with rabbit anti-human AGE-R1 (50 to 100
BCA protein assay method (Pierce).mg/mL) and rat anti-human AGE-R3 IgG (10 to 20
mg/mL) [18] at room temperature (RT) for one hour Ligand blot and Western blot analyses
followed by biotin-conjugated goat anti-rabbit or anti-
Ligand blotting was carried out as described pre-rat antibody (20 to 50 mg/mL; Amersham Life Science
viously [13]. Briefly, 10 to 20 mg cell or tissue membraneInc., Cleveland, OH, USA) and streptavidin-conjugated
fractions in Laemli sample buffer containing 2% b-mer-FITC (Zymed Laboratories, Inc., San Francisco, CA,
captoethanol were heated at 958C for five minutes andUSA). Anti–AGE-R2 IgG did not exhibit sufficient
were electrophoresed [12% sodium dodecyl sulfate-poly-staining on renal tissue sections. The sections were exam-
acrylamide gel electrophoresis (SDS-PAGE)]. Gels wereined and coded, and the fluorescence intensity was
transferred to nitrocellulose (NC) membranes (0.2 mmgraded in a blinded fashion on a 0 to 41 scale.
pore size) using a mini-gel transfer apparatus (Bio-Rad).
The NC membranes were blocked with 2% BSA in PBSAGE binding to intact NOD mesangial cells
for one hour, washed twice with PBS containing 0.05%
Confluent MCs from each group of mice were grown Tween-20, and probed with 4 3 106 cpm 125I-AGE-BSA
in six-well culture dishes and were incubated in binding for one hour in the presence or absence of cold AGE-
medium consisting of complete DMEM and 1% BSA BSA (3100 excess). The blots were washed extensively
[9, 11, 31] for 30 minutes at 48C. 125I-AGE-BSA or 125I- with PBS/Tween-20, air dried, and exposed to XAR film
BSA was added at different concentrations in the pres- (Kodak, Rochester, NY, USA) at 2808C. The radioactiv-
ence or absence of 100-fold excess of unlabeled ligand ity associated was quantitated by a phosphoimager
(AGE-BSA, BSA) for four hours at 48C or for one hour (Packard, Downers Grove, IL, USA) and expressed as
at RT. Cells were washed extensively with cold PBS and the percentage of cpm of specific protein species/total
then lyzed using 0.1 mol/L NaOH. The radioactivity and cpm of respective lane. This procedure was repeated at
protein content (BCA-protein analysis; Pierce) in each least three times using membrane extracts from different
sample were measured. Competitive inhibition assays cell preparations.
were also performed by incubating cells with 125I-AGE- For Western blotting, samples of membrane fractions
BSA (,3 3 106 cpm/well) and increasing amounts of cold were electrophoresed and transferred to NC membranes,
ligand. All experiments were carried out in triplicate, and as described previously in this article. The membranes
data were evaluated by Scatchard analysis. In separate were blocked with 2% dry milk in PBS/Tween-20 for
experiments, the effects of excess glucose (40 mmol/L), one hour, washed twice, and incubated with the indicated
insulin (1 to 100 U/mL), and IGF-1 (1 to 10 mg/mL) on amount of receptor primary antibody for one hour. The
ligand binding were evaluated after incubation of NOD appropriate peroxidase-conjugated secondary antibody
MC to these reagents for up to 72 hours. was added at a final dilution of 1:2000 for one hour. The
bands were detected using the electrochemilumines-
Preparation of membrane fractions from mesangial cence method (ECL; Amersham). Equal sample loading
cell and kidneys onto membranes was checked using Amido black stain-
Mesangial cell monolayers were harvested by gentle ing subsequent to Western or ligand blotting.
scraping and washing in PBS and were centrifuged at
RNA isolation and reverse transcription-polymerase500 3 g for five minutes and disrupted with a tight
chain reactionDounce homogenizer in a solution of PBS containing 1
mmol/L ethylenediaminetetraacetic acid (EDTA) and a Total RNA was extracted from kidney cortex or cul-
tured MCs using RNAzol solution (TET-TEST Inc.,protease inhibitor cocktail of 1 mmol/L benzamidine, 5
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0.005; Fig. 1B) compared with the genetically related,
ILE (Fig. 1), or SJL controls (data not shown) [30]. Age-
matched diabetic (,1 month of diabetes) NOD mice
exhibited greater AGE levels than the ILE controls
(serum: . sixfold, P , 0.005, and kidney approximately
fourfold, P , 0.01; Fig. 1). AGE levels in sera and kidney
tissue continued to rise as a function of age in all groups
(up to 6 months, data not shown).
AGE-receptor mRNA and protein expression in NOD
kidney cortex membrane
Fig. 1. Elevated advanced glycation end product (AGE) levels in se-
To test the level of renal tissue expression of the differ-rum (A) and kidneys (B) of prediabetic (ND-NOD) or newly diabetic
(D-NOD) nonobese diabetic mice versus nondiabetic ILE. Serum and ent receptor genes, quantitative reverse transcription-
renal cortical sections from each strain of mice (age of 3 months, N 5 PCR (RT-PCR) was used [30, 31]. ND-NOD renal tissue
20 per group) were processed for AGE determination by an AGE-
AGE-R1 mRNA level was approximately threefoldspecific ELISA [27, 35]. Data are expressed as the means 6 SD AGE
U/mL of serum or U/mg tissue protein, with each sample tested in lower than in ILE mice (P , 0.01; Fig. 2), as was AGE-
triplicate. *P values , 0.05 vs. ILE control. R1 protein, by Western blotting (Fig. 3). In contrast,
AGE-R2 and AGE-R3 mRNA (Fig. 2) and protein level
(Fig. 3) were either unchanged or moderately elevated
in both ND-NOD (-R2, P 5 NS, -R3, P , 0.01) andFriendswood, TX, USA) for assessing AGE-R1, AGE-
D-NOD (-R2, P 5 NS, -R3 P , 0.005) compared withR2, AGE-R3, ScR-II, and RAGE mRNA expression.
ILE mice (Figs. 3 and 4). To test the relative expressionOne microgram of total RNA was reverse transcribed
level of other AGE-recognizing gene products in predia-to cDNA. PCR was performed as described [30, 31] using
betic renal cortex, mRNA expression of ScR-II anda Perkman Cetus kit. The following primers were used:
RAGE was evaluated by RT-PCR: Neither of them dif-AGE-R1: sense, GCT, CTT, CCA, CTC, CTT, ACT,
fered significantly from the control ILE tissue extracts;
CCT, and antisense, CCA, GAC, AGG, CAA, CTA,
however, after the onset of hyperglycemia (within 4
TGA, AC; AGE-R2: sense, TGG, TGT, GGT, GGC,
weeks), a notable rise was observed in both (RAGE, 2-
TAT, TGA, CCT, TTG, C, and antisense, CGC, AGT, fold, P 5 NS; ScR-II, 2.5-fold, P 5 NS; Fig. 2 A, B), a
AGT, CGT, CGT, TCA, CCT, GAT, C; AGE-R3: sense, pattern that resembled that of AGE-R3 expression.
CAC, CTG, CAC, CTG, GAG, TCT, AC, and antisense,
GCA, CTG, GTG, AGG, TCT, ATG, TC; ScR-II: sense, AGE-receptor immunostaining of NOD kidney
AGA, CCT, TCT, GCT, GTT, CCC, CT, and antisense, tissue sections
CCC, TGG, GAC, AGT, GTT, CTC, TGG, TT; and Based on the previously mentioned findings, we exam-
RAGE: sense, CCT, GGG, AAG, CCA, GAA, ATT, ined the relative immunoreactivity (IR) of AGE-R1 on
and antisense, ACA, CAG, GTC, AAG, GTC, ACA. renal cortex from NOD mice. Compared with kidney
The mutants were made by creating a deletion in the sections from ILE controls, which displayed a distinct
original PCR product [24], and competitive PCR was glomerular AGE-R1 staining pattern (Fig. 4B), AGE-
performed by adding a different amount of mutant to R1 IR was nearly undetectable in prediabetic NOD mice
each cDNA amplification tube. After electrophoresis of (Fig. 4C) but was comparable to normal after onset of
PCR products, each band was quantitated by computer- diabetes (Fig. 4D). In contrast, AGE-R3 staining, which
assisted densitometric analysis. The ratio of unknown was positive in ND-NOD (Fig. 4G), was considerably
cDNA/mutant was measured for each molecule. A com- more pronounced after diabetes (Fig. 4H); preimmune
petitive PCR for b-actin (sense, GTG, GGC, CGC, TCT, rabbit IgG or isotypic rat IgG control was negative (Fig.
AGG, CAC, CA; antisense, TGG, CCT, TAG, GGT, 4 A, E). Anti-R2 IgG did not exhibit sufficient sensitivity
GCA, GGG, GG) was also performed for each sample, on tissue sections (data not shown).
and the data were expressed as the ratio of AGE-R to
AGE-receptor mRNA and protein levels in NODb-actin mRNA level.
mesangial cells
To assess whether the differences in receptor expres-RESULTS
sion seen in whole renal tissue was also reflected on
AGE levels in kidneys and sera from NOD mice MCs, MCs from each strain were isolated [9, 30, 31] and
Prediabetic ND-NOD mice (3 to 4 months old) exhib- evaluated with a focus on AGE-R1, AGE-R2, and AGE-
ited approximately twofold to threefold greater levels of R3 mRNA and protein expression by Western analyses.
AGE-R1 mRNA levels were markedly attenuated inAGE in serum (P , 0.025; Fig. 1A) and in kidneys (P ,
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Fig. 2. Low AGE-R1 mRNA levels in predi-
abetic ND-NOD and D-NOD versus control
ILE mouse kidney cortex. (A) Densitometric
analysis of competitive RT-PCR data on
AGE-R1, AGE-R2, AGE-R3, RAGE, and
ScR-II expression from total RNA extracts of
kidney cortex from NOD and ILE mice as per
Figure 1 (N 5 8 per group). (B) Representa-
tive competitive RT-PCR data on each mole-
cule tested(A). Data are expressed as the
mean ratio 6 SD of each component/mutant
to b-actin/mutant mRNA. *P , 0.01, AGE-R1
in ND-NOD vs. ILE; AGE-R3 in ND-NOD
vs. ILE, **P , 0.05, AGE-R3 in D-NOD vs.
ILE and ND-NOD.
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Fig. 3. AGE-R1 protein level is low in prediabetic ND-NOD compared
with nondiabetic control ILE mouse kidney cortex. AGE-R1, AGE-
R2, and AGE-R3 levels were determined by Western blot analysis on
cortical membrane extracts from ND-NOD, D-NOD, and ILE mice
(N 5 5 per group). Samples were separated on 12% polyacrylamide
gels, transferred, immunoblotted with the respective antibody, and then
visualized by ECL (anti-AGE-R1, 50 mg/mL, anti-AGE-R2, 50 mg/mL,
AGE-R3, 10 mg/mL). Molecular weights are indicated on the right side
of the panel. The protein concentration used was 20 mg/lane. Data are
representative of five identical experiments.
ND-NOD MCs compared with ILE and D-NOD MCs
(Fig. 5A), while AGE-R2 and AGE-R3 mRNA were
enhanced (Fig. 5A). Consistent with the mRNA pattern,
Fig. 4. AGE-R1 immunofluorescence is reduced in prediabetic ND-AGE-R1 protein was nearly undetectable in ND-NOD
NOD versus nondiabetic ILE mouse kidney cortex. Frozen cortical
MC membrane fractions, in contrast to AGE-R2 and kidney sections from ND-NOD, D-NOD, and ILE mice (N 5 20 per
group) were incubated with rabbit anti-human recombinant AGE-R1AGE-R3, which were either unchanged or enhanced in
IgG (50 mg/mL) or rat anti-mouse AGE-R3 monoclonal antibody (10relationship to control (Fig. 5B).
mg/mL) followed by goat anti-rabbit or anti-rat IgG biotin-conjugated
antibodies and streptavidine-conjugated FITC. (A–D) AGE-R1. (E–H )
AGE-receptor sites and binding affinity on NOD AGE-R3. (A and E) Nonimmune IgG. (B and F) ILE mice. (C and
G) ND-NOD mice. (D and H) D-NOD mice. Magnification 3200.mesangial cells
To link the variable AGE-R gene expression to the
AGE-specific ligand binding activity exerted by all AGE-
R components present on MCs from NOD mice, radioli- 6C), presumably corresponding to AGE-R1 (as binding
gand-binding assays were performed on MCs isolated was blocked by anti-AGE-R1 IgG); AGE binding by D-
from each NOD strain. AGE-binding activity on MCs NOD MC membrane was comparable to and not ex-
from prediabetic ND-NOD mice was markedly sup- ceeding that of control ILE (Fig. 6C). Additional experi-
pressed compared with D-NOD or ILE (by .60%, P , ments were performed on cultured NOD MCs and were
0.05 in either comparison), consistent with an estimated incubated with excess concentrations of d-glucose, insu-
1.6 3 106 binding sites per cell from ND-NOD versus lin, or IGF-1 for varying time periods. No effects were
6.6 3 106 and 7.0 3 106 sites per cell from ILE and D- observed on subsequent AGE ligand-binding studies
NOD mice (P , 0.002 and P , 0.005, respectively; Fig. (data not shown).
6B), while the binding affinity did not vary significantly
(Ka, 160 to 300 nmol/L in all three strains; Fig. 6B) from
DISCUSSIONthat reported previously for mouse strains [9, 11]. Ligand
blot analysis on membrane extracts from the same cell The previously mentioned studies present the first evi-
dence, to our knowledge, of altered in vivo expressionpreparations demonstrated low AGE-binding activity on
ND-NOD MCs, compared with ILE, associated with a and binding activity of kidney-specific AGE-R in con-
nection with premature AGE deposition in NOD mice,single approximately 48 to 50 kD protein species (Fig.
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Fig. 5. AGE-R1 mRNA and membrane pro-
tein levels are low in MCs isolated from predi-
abetic ND-NOD mice versus MCs from nondi-
abetic ILE MCs. (A) RT-PCR: Total RNA
was extracted from mouse MCs (N 5 5 mice/
group) and analysis was performed as in Fig-
ure 2. Densitometric data of five identical tests
performed on five mice/group are shown
(*P , 0.01, ND-NOD AGE-R1 vs. ILE, *P ,
0.05 ND-NOD AGE-R3 vs. ILE). (B) West-
ern blot analysis was performed on ND-NOD
and ILE mouse MC membrane, as in Figure 3.
After transfer, 10 mg of MC membrane protein
were incubated with the respective anti–
AGE-R IgG and visualized by ECL. Data are
representative of five independent experi-
ments.
Fig. 6. Mesangial cells (MCs) from predia-
betic ND-NOD mice exhibit low number of
AGE-specific binding sites compared to non-
diabetic ILE MC. (A) Specific 125I-AGE-BSA-
binding: Cultured MCs from age-matched
ND-NOD, D-NOD, and ILE mice (N 5 3
mice per group) were incubated with 125I-
AGE-BSA alone (25 mg/mL) plus a 100-fold
excess amount of cold AGE-BSA for four
hours at 48C or 125I-BSA (25 mg/mL; hatched
bars) or 125I-AGE-BSA. Data are expressed
as the means 6 SD of specific binding (total
minus 2 nonspecific) cpm/106 cells from three
independent measurements, each done in trip-
licate wells. (B) Scatchard analysis of specific
binding data from each strain are indicated
by arrows. (C) Ligand blot: 125I-AGE-BSA
binding by membrane preparation of MC used
in studies shown (A and B) and revealed by
autoradiography. Note the marked reduction
of ligand binding by a 48 kD species on ND-
NOD membrane.
a model of insulin-dependent diabetes (T1D) that is also emerged as a possible mechanistic explanation for the
early renal lesions in this model. After the onset of diabe-prone to nephropathy [28–30]. Since abnormal AGE
deposits appear prior to the development of hyperglyce- tes, impeded AGE removal could act together with hy-
perglycemia-mediated mechanisms to precipitate dia-mia, a delay in the physiologic turnover of tissue AGEs
He et al: Abnormal AGE-R expression and renal disease1938
betic nephropathy (DN). The findings support a possible cantly below the level of the corresponding wild-type
mouse, a trend directionally countered to the distinctassociation between impaired AGE processing, differen-
tial expression of AGE-R genes, and susceptibility to rise in tissue AGE and independent of hyperglycemia.
AGE-R1, a 48 kD AGE-binding molecule [13, 14], ex-nephropathy in this model [30]. Since a significant sub-
population (.30%) of diabetic humans are prone to hibits distinct extracellular, transmembrane, and cyto-
plasmic domains, a structure that is typically thought tosevere DN [1, 2], the findings may carry certain implica-
tions for the human diabetic renal disease, even though facilitate ligand binding and endocytosis. The protein is
found on both cell surface and intracellular RE organelleno animal model develops lesions identical to those of
human diabetic kidneys. membranes; its reported physical association to oligosac-
charide transferases is suggestive of a role in their stabil-A two-step process is considered to lead to the elimina-
tion of AGE-modified macromolecules in the absence ity and possibly in intracellular AGE detoxification.
To confirm that AGE-R1 underexpression occurredof hyperglycemia: (1) a peripheral or systemic step, by
which tissue AGEs once formed are degraded locally in cells native to the glomerulus, native MCs from these
mice were tested in culture. AGE-R1 expression andvia receptor-dependent [26] or nonspecific proteolytic
mechanisms; and (2) an excretory step, involving the AGE ligand binding were both suppressed in MCs from
prediabetic NOD mice. Here again, AGE-binding capac-clearance of AGE degradation products by the urinary
system [25, 27]. Receptor-dependent AGE binding and ity of MC taken after the onset of diabetes failed to
rise above the nondiabetic ILE. Indeed, whether usingdegradation has been found enhanced in response to
excess AGE in vitro [24] or in insulin-deficient diabetic complex kidney tissue or a single cell type (MC), a consis-
tent pattern of underexpression and/or low respon-animal models [34], a self-regulatory property that is key
to tissue AGE homeostasis [35]. The animals used in siveness to AGE and/or diabetes were found limited to
one receptor component, AGE-R1. In addition, this wasthis study were of an age not associated with renal dys-
function, pointing to an alteration in the systemic phase, linked to reduced AGE-R sites on prediabetic cell sur-
face, despite the rise in expression levels of AGE-R3possibly at the AGE-R level.
Among the cellular components of the kidney, MCs and other receptor molecules, suggesting that AGE-R1–
mediated AGE turnover is important to normal homeo-display AGE-Rs that are active in the uptake, processing,
and degradation of AGEs [9, 10, 13]. Because of the stasis. Impaired AGE-R1 gene function may be naturally
shared by other renal or extrarenal cells involved in theabundance of MCs in the glomerulus, these cells could be
important in the processing of glomerular AGEs [3, 8]. disposal of altered macromolecules, namely macro-
phages [3, 4, 35]. The latter was indeed indicated inWhile some receptors serve in the removal of AGEs,
others, such as RAGE [23, 24], ScR-II [21, 22], and AGE- studies of NOD mouse peritoneal macrophages (unpub-
lished data). These findings stand in contrast to the re-R3 [18–20], have been implicated in the regulation of cell
growth or cell–matrix interactions, regardless of etiology ported enhanced AGE binding and degradation in dif-
ferent diabetic models, for example, alloxan-induced[12]. Extracellular and intracellular AGEs are known
enhancers of oxidative stress [23, 36] and cell activation, C57BL6 or db/db KsJ mice [34], further pointing to a
NOD-specific receptor defect. Moreover, since all iso-including the up-regulation of several AGE-receptor
(AGE-R) genes, for example, AGE-R2, AGE-R3, and lates of MCs were cultured under identical conditions,
the sustained phenotype of subnormal AGE-R1 expres-RAGE [23, 24, 32, 35], which can then trigger inflamma-
tory events [4, 7, 8, 24]. It is thus evident that a loss or sion and activity during culture suggest a genetic regula-
tory or mutational defect unrelated to the diabetic envi-negative balance in AGE-removing receptors could lead
to excessive AGE, which could in turn act as a stimulus ronment. Whether such a defect is primary or secondary
is not clear at this point.for the proinflammatory type of AGE-Rs. The actual
players in the unexplained abundance of tissue AGE in Young NOD kidneys overexpress growth factors
(TGF-b1) and ECM components [30, 31]. Although ofthe NOD mice are not identified, but could include a
defective AGE-removal pathway. unclear mechanism, this finding could be in part attrib-
uted to premature kidney AGE accumulation, inducingOf the five AGE-related receptor molecules tested in
NOD renal tissue, AGE-R1 was the only component those AGE-R known to trigger activation-dependent
events, namely AGE-R3, RAGE, or ScR-II. Amongfound to exhibit a consistent pattern of underexpression,
compared with the wild type, at the transcriptional and these, AGE-R3 induction was the most prominent, even
in prediabetic NOD. AGE-R3 or galectin-3 has beentranslational levels, as well as in AGE-binding activity.
This was most evident at the prediabetic stage, and even known to promote growth and anti-apoptotic events [18–
20, 22, 32]. Induction of this gene by high tissue AGEafter four months of hyperglycemia, it never exceeded
the nondiabetic level of the wild-type control. The NOD levels leads to cell-surface AGE-R3 overexpression and
enhanced ligand-binding activity [18]. However, the pro-mouse is thus far the only strain in which the expression
and activity of an AGE-binding molecule are signifi- cess of endocytosis and degradation of AGEs may be
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dictated by a combination of factors. For instance, a APPENDIX
threshold of AGE-R1 synthesis and dislocation to the Abbreviations used in this article are: ACE, angiotensin converting
enzyme; AGE, advanced glycation end product; AGE-R, advancedcell surface may be required, below which AGE-R3 can-
glycation end product-receptor; BSA, bovine serum albumin; D-NOD,not form thiol ester-dependent AGE-binding complexes
nonobese diabetic mice; ECM, extracellular matrix; IDDM, autoim-
for high-efficiency ligand internalization [18]. Indeed, mune type 1 diabetes; MC, mesangial cell; ND, nondiabetic; NOD,
nonobese diabetic mice; OST, oligosaccharyl-transferase; PBS, phos-the AGE-binding capacity of diabetic MCs was clearly
phate-buffered saline; PMSF, phenylmethylsulphonyl fluoride; RAGE,subnormal despite the pronounced increase in AGE-R3 receptor for advanced glycation end product; RT, room temperature;
expression. ScR-II, scavenger receptor (class II).
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